%0 Journal Article
%A Brenner, Juliette
%A Bastiaansen, Anna E. M.
%A Guasp, Mar
%A Muñiz-Castrillo, Sergio
%A Iizuka, Takahiro
%A de Bruijn, Marienke A. A. M.
%A Muñoz-Lopetegi, Amaia
%A Martínez-Hernández, Eugenia
%A Picard, Géraldine
%A Vogrig, Alberto
%A Millot, Mathilde
%A Finke, Carsten
%A Geis, Christian
%A Lewerenz, Jan
%A Melzer, Nico
%A Prüss, Harald
%A Räuber, Saskia
%A Ringelstein, Marius
%A Rostàsy, Kevin
%A Sühs, Kurt-Wolfram
%A Thaler, Franziska S.
%A Wandinger, Klaus-Peter
%A Wurdack, Katharina
%A Crijnen, Yvette S.
%A Kerstens, Jeroen
%A van Steenhoven, Robin W.
%A Veenbergen, Sharon
%A Schreurs, Marco W. J.
%A van den Berg, Robert
%A Volovici, Victor
%A Neuteboom, Rinze F.
%A de Vries, Juna M.
%A Sillevis Smitt, Peter A. E.
%A Nagtzaam, Mariska M. P.
%A Franken, Suzanne C.
%A Ratuszny, Dominica
%A Menge, Til
%A Bertolini, Annikki
%A Bien, Christian
%A Berger, Robert
%A Tauber, Simone
%A Angstwurm, Klemens
%A Seifert-Held, Thomas
%A Kraft, Andrea
%A Klausewitz, Jaqueline
%A Ayzenberg, Ilya
%A Eisenhut, Katharina
%A Roessling, Rosa
%A Heiden, Martha
%A Kümpfel, Tania
%A Dalmau, Josep
%A Leypoldt, Frank
%A Honnorat, Jérôme
%A Titulaer, Maarten J.
%T Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study
%J The lancet / Regional health. Europe
%V 62
%@ 2666-7762
%C [Amsterdam]
%I Elsevier
%M DZNE-2025-01431
%P 101562
%D 2026
%Z Funding: This study was funded by Dioraphte (charity; project 2001 0403).
%X Background: Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment. We aimed to refine the anti-NMDAR Encephalitis One-year functional Status (NEOS) score by developing NEOS2, an updated model using readily available data at the time of diagnosis. We assessed the predictive value of the NEOS2-score for (1) improvement following first-line treatment, (2) functional outcome at one-year follow-up, and (3) resumption of school or work within three years. Methods: In this international (France, Germany, Japan, the Netherlands and Spain) cohort study in patients with a definite anti-NMDAR encephalitis diagnosis (according to the clinical criteria plus antibody testing in CSF), we performed logistic regression analyses to develop and validate multivariable models to predict -based upon variables available at diagnosis- short (ΔmRS two weeks after first-line treatment), middle (modified Rankin Scale [mRS] at one year), and long-term (return to school or work within three years) outcomes. We included clinical variables and biomarkers available at diagnosis. Findings: We included 702 patients (mean age 23 years, 95
%F PUB:(DE-HGF)16
%9 Journal Article
%R 10.1016/j.lanepe.2025.101562
%U https://pub.dzne.de/record/283019